ETFs with ALXN as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|5.65%||First Trust Amex Biotechnology Index Fund (FBT)||+1.63 (2.56%)|
|5.52%||PowerShares Dynamic Biotech &Genome (PBE)||+2.45 (7.47%)|
|4.41%||iShares NASDAQ Biotechnology Index Fund (IBB)||+16.98 (8.65%)|
|2.26%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+0.92 (0.76%)|
|1.83%||First Trust NASDAQ-100 Ex-Technology Sector Index Fund (QQXT)||+2.26 (7.25%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, and atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. ... More ...